Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Clinuvel Pharmaceuticals Limited
  6. News
  7. Summary
    CUV   AU000000CUV3

CLINUVEL PHARMACEUTICALS LIMITED

(CUV)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Clinuvel Pharmaceuticals : Books $11 Million Cash Receipts in Fiscal Q4

07/30/2021 | 03:29am EDT


ę MT Newswires 2021
All news about CLINUVEL PHARMACEUTICALS LIMITED
09/21CLINUVEL PHARMACEUTICALS : Confirms AGM Date
PU
09/13CLINUVEL PHARMACEUTICALS : Presentation H.C. Wainwright Global Investment Conference
PU
09/02CLINUVEL PHARMACEUTICALS LIMITED : Ex-dividend day for final dividend
FA
08/26CLINUVEL PHARMACEUTICALS : Investor Webinar Financial Results
PU
08/26CLINUVEL PHARMACEUTICALS' : Net Profit Jumps 64% on Higher Drug Demand
MT
08/25CLINUVEL PHARMACEUTICALS : Newsletter 4 - August 2021
PU
08/25CLINUVEL PHARMACEUTICALS : Corporate Presentation - FY2021 Results
PU
08/25CLINUVEL PHARMACEUTICALS : Delivers Record Revenues and Profit
PU
08/25Clinuvel Pharmaceuticals Limited Declares Annual Unfranked Dividend for the Year Ending..
CI
08/25CLINUVEL PHARMACEUTICALS : Appendix 4E and Preliminary Financial Report
PU
More news
Financials
Sales 2022 64,6 M 46,8 M 46,8 M
Net income 2022 30,9 M 22,4 M 22,4 M
Net cash 2022 108 M 78,2 M 78,2 M
P/E ratio 2022 66,0x
Yield 2022 0,11%
Capitalization 1 989 M 1 437 M 1 442 M
EV / Sales 2022 29,1x
EV / Sales 2023 20,1x
Nbr of Employees -
Free-Float 79,2%
Chart CLINUVEL PHARMACEUTICALS LIMITED
Duration : Period :
Clinuvel Pharmaceuticals Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CLINUVEL PHARMACEUTICALS LIMITED
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 40,25 AUD
Average target price 33,92 AUD
Spread / Average Target -15,7%
EPS Revisions
Managers and Directors
Philippe Jacques Wolgen Chief Executive Officer, MD & Director
Darren M. Keamy Chief Financial Officer & Secretary
Willem A. Blijdorp Chairman
Dennis J. Wright Chief Scientific Officer
Lachlan Hay Global Director-Operations
Sector and Competitors
1st jan.Capi. (M$)
CLINUVEL PHARMACEUTICALS LIMITED80.33%1 437
CSL LIMITED9.61%102 198
WUXI BIOLOGICS (CAYMAN) INC.18.19%66 153
SAMSUNG BIOLOGICS CO.,LTD.12.95%52 008
BIOGEN INC.20.70%44 045
ALEXION PHARMACEUTICALS, INC.0.00%40 336